Global Oncology Biosimilars Market Size By Type (mAb, Immunomodulators), By Application (Retail Pharmacies, Hospital Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Oncology Biosimilars Market was valued at USD 13.1 billion in 2023 and is projected to reach USD 39.7 billion by 2031, growing at a robust CAGR of 14.9% during the forecast period from 2023 to 2031. The rapid expansion of the market is fueled by the increasing prevalence of cancer worldwide, rising demand for cost-effective biologic therapies, and an expanding pipeline of biosimilar products approved for oncology indications. Oncology biosimilars are gaining traction due to their ability to offer similar efficacy and safety as branded biologics at significantly lower costs, thus enhancing accessibility to cancer treatment in both developed and emerging markets.

Drivers:

1. Rising Cancer Incidence Globally:

An increasing number of cancer diagnoses each year is driving demand for effective and affordable treatment options. Biosimilars help address this need by providing budget-friendly alternatives to high-cost biologics.

2. Cost Containment in Healthcare:

Payers and governments are under pressure to reduce healthcare expenditure. The adoption of biosimilars, especially in oncology where treatment costs are high, supports cost containment without compromising clinical outcomes.

3. Patent Expirations of Blockbuster Biologics:

The expiration of patents for several key oncology biologics, such as trastuzumab and bevacizumab, is opening doors for biosimilar entrants, driving market growth.

Restraints:

1. Regulatory and Development Complexity:

Developing biosimilars is a complex process requiring rigorous regulatory compliance and clinical trials to demonstrate biosimilarity, which can deter new entrants and slow time-to-market.

2. Physician and Patient Reluctance:

Despite clinical equivalence, some healthcare providers and patients remain hesitant to switch from originator biologics to biosimilars due to limited awareness or perceived differences in efficacy and safety.

Opportunity:

1. Expansion in Emerging Markets:

Emerging economies in Asia-Pacific and Latin America present untapped growth potential as governments focus on increasing access to affordable cancer care through biosimilars.

2. Collaborations and Strategic Licensing:

Partnerships between biosimilar developers and major pharmaceutical companies are accelerating market penetration and increasing geographic reach.

Market by System Type Insights:

The Monoclonal Antibodies segment led the market in 2023, accounting for the largest share. These biologics are commonly used for treating cancers like breast, colorectal, and lymphoma. The demand for monoclonal antibody biosimilars continues to grow due to their wide therapeutic applications and high treatment costs, making biosimilars a financially viable alternative.

Market by End-use Insights:

Hospitals emerged as the dominant end-use segment in 2023. Hospitals are key purchasers of oncology biosimilars due to their volume-based procurement systems and need for cost-effective, scalable cancer treatments. The retail pharmacies segment is also expected to grow, driven by expanding outpatient chemotherapy and oral biosimilar therapies.

Market by Regional Insights:

North America held the largest market share in 2023, owing to high cancer prevalence, supportive regulatory pathways, and a strong biosimilar adoption framework. Asia-Pacific is expected to witness the highest CAGR during the forecast period, driven by healthcare reforms, growing cancer burden, and government support for biosimilar adoption in countries such as India, China, and South Korea.

Competitive Scenario:

Prominent players in the global oncology biosimilars market include Amgen Inc., Pfizer Inc., Celltrion Healthcare, Biocon Biologics Ltd., Samsung Bioepis, Sandoz (a Novartis division), Mylan N.V., Teva Pharmaceutical Industries Ltd., STADA Arzneimittel AG, and Fresenius Kabi. These companies are focusing on expanding product pipelines, forming strategic alliances, and enhancing production capabilities to strengthen their competitive position.

Scope of Work – Global Oncology Biosimilars Market:

Key Market Developments:

2023: Amgen Inc. launched a new biosimilar version of bevacizumab in the U.S. and Europe, expanding its oncology portfolio.

2024: Biocon Biologics entered a strategic collaboration with a European pharma giant to co-develop and market multiple oncology biosimilars.

2025: Pfizer announced FDA approval for its biosimilar trastuzumab for the treatment of HER2-positive breast cancer.

FAQs:

1) What is the current market size of the Global Oncology Biosimilars Market?

The market was valued at USD 13.1 billion in 2023.

2) What is the major growth driver of the Global Oncology Biosimilars Market?

The rising global incidence of cancer and the increasing demand for cost-effective treatment options are key growth drivers.

3) Which is the largest region during the forecast period in the Global Oncology Biosimilars Market?

North America currently holds the largest market share, but Asia-Pacific is expected to grow fastest.

4) Which segment accounted for the largest market share in Global Oncology Biosimilars Market?

The Monoclonal Antibodies segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Oncology Biosimilars Market?

Major players include Amgen Inc., Pfizer Inc., Biocon Biologics Ltd., Samsung Bioepis, and Sandoz.

Let me know if you'd like this exported to Word format or tailored for a particular use case (e.g., pitch deck, executive summary).